What question did this study set out to answer?

To evaluate the maintenance of clinical remission in IBD patients after switching from intravenous to subcutaneous infliximab administration.

January 23, 2026Journal of Crohn s and Colitis

P1057Maintenance of Inflammatory Bowel Disease remission after switching from iv to sc administration of infliximab - a prospective single center cohort study

View Full Paper

Ask AI

Bookmark

To evaluate the maintenance of clinical remission in IBD patients after switching from intravenous to subcutaneous infliximab administration.
Prospective, observational, single center cohort study
Switched patients from mIFX intravenous to subcutaneous every 4 weeks
Measured serum infliximab trough levels before the switch and after 24 weeks
Assessed clinical remission using partial Mayo score and Harvey-Bradshaw Index
92.6% of Crohn's disease patients maintained clinical remission at week 24
100% of ulcerative colitis patients remained in remission
Significantly increased percentage achieved target serum infliximab levels before the switch (92.9% in perianal CD, 96.4% in non-perianal CD and UC)
Quality of life and patient satisfaction remained high with subcutaneous administration

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective cohort study shows effective maintenance of remission in IBD after switching infliximab to subcutaneous form, suggesting a timely transition is beneficial.

Cite This Study

Ocepek et al. (2026) studied this question.

synapsesocial.com/papers/69730f18c8125b09b0d1ee37 https://doi.org/10.1093/ecco-jcc/jjaf231.1238

View Full Paper

Ask AI

Bookmark

Implication

Prospective cohort study shows effective maintenance of remission in IBD after switching infliximab to subcutaneous form, suggesting a timely transition is beneficial.

P1057Maintenance of Inflammatory Bowel Disease remission after switching from iv to sc administration of infliximab - a prospective single center cohort study

Key Points

Discussion

Implication

Cite This Study

P1057Maintenance of Inflammatory Bowel Disease remission after switching from iv to sc administration of infliximab - a prospective single center cohort study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider